The SA gene has been shown to be much more highly expressed in the kidneys of spontaneously hypertensive rats than in the corresponding wild-type strain. Genetic polymorphism of this gene has been shown to play a role in human hypertension, although the details of this association remain controversial. We investi- 
Introduction
Immunoglobulin A nephropathy (IgAN), which is characterized by immunoglobulin A (IgA) deposits in the glomerular mesangium, is the most prevalent form of primary glomerulonephritis and the major cause of end stage renal disease (ESRD) (1, 2) . IgAN is a complex disease in which familial clustering is suggestive of an inherited genetic predisposition (3, 4) . It has a variable clinical course, with one-third of IgAN patients progressing to ESRD within 10-20 years of strated to cosegregate with blood pressure in both the SHR/ WKY and Dahl rat models (9) (10) (11) . In humans, the SA gene is located on chromosome 16p13.11, and a difference in allele frequency of the SA polymorphism between hypertensives and controls has been reported (12) , although the results of other previous reports remain controversial (13, 14) .
In this study, we attempted to investigate the possible role of the SA gene polymorphism in kidney disease. We also studied any possible associations between the SA gene variation and the clinical manifestations in patients with IgAN as well as those in controls without any history of renal disease.
Methods
The ethics committee of the institution involved approved the protocol for the study, and informed written consent for the genetic studies was obtained from all participants. Genomic DNA of peripheral blood cells was isolated by an automatic DNA isolation system (NA-1000; Kurabo, Osaka, Japan) from 374 Japanese individuals, including 274 patients with histologically confirmed IgAN. Patients with Schonlein-Henoch purpura or secondary IgAN, such as cases of hepatic glomerulosclerosis, were excluded from the analysis. Diagnosis of IgAN was based on a kidney biopsy that revealed the presence of dominant or co-dominant glomerular mesangial deposits of IgA as assessed by an immunofluorescence examination. Investigated clinical characteristics of the patients with IgAN included age, sex, duration of observation (in months), level of urinary protein excretion (g/day), serum creatinine (sCr; mg/dl), and 24-h creatinine clearance (CCr; ml/min). The time from the first urine abnormality to renal biopsy (in months) was also recorded for the 223 of the 274 patients whose first episode of urine abnormality (proteinuria or hematuria) could be clearly defined. At the time of renal biopsy, the advanced type of glomerulonephritis (GN) was defined by a sCr level greater than 1.2 mg/dl or a 24-h CCr of less than 70 ml/min. Hypertension was defined by the use of one or more antihypertensive medications and/or a blood pressure greater than or equal to 140 mmHg systolic or 90 mmHg diastolic. The primary endpoint (ESRD; end stage renal disease) was defined as the date at which the sCr levels doubled after the time of diagnosis, or when patients underwent their first hemodialysis.
The administrations of glucocorticoids, antihypertensive agents, and angiotensin converting enzyme inhibitors (ACEIs) were also recorded for each patient.
The genotypes in 100 patients with no history of renal disease (46 females and 54 males, of which 36 were normotensive and 64 hypertensive; age, 56.3 9.3) were studied, and any associations between the genotype and hypertension were also investigated.
Genotype Determination
We studied a single nucleotide polymorphism in the SA gene by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) according to the method described previously (14) . PCR of the genomic DNA was performed to amplify a 315-base pair (bp) fragment in the SA gene using the primer pair 5 -GTCACACATTAGGGCA GCTGCACAC-3 and 5 -GCCAGGCATGGTGATGCAAT CCTG-3 . The reaction mixture contained 1 PCR buffer, 1.5 mmol/l MgCl2, 200 mmol/l deoxynucleotide triphosphates (dNTPs), 1 unit Taq DNA polymerase (Takara, Kyoto, Japan), 10 pmol of each primer, and 50-100 ng genomic DNA. The PCR amplification reaction consisted of one cycle at 95 ºC for 5 min, followed by 30 cycles of denaturation at 94 ºC for 15 s, annealing at 62 ºC for 15 s, and an extension at 72 ºC for 30 s. The final extension was performed at 72 ºC for 5 min. The PCR products were digested with restriction endonuclease PstI (Promega, Madison, USA), and electrophoresed on a 3% agarose gel. For A2 alleles, this resulted in a fragment of 230-bp and one of 85-bp fragment, whereas the 315-bp A1 alleles lacked the restrictive site.
Statistical Analysis
Continuous variables were compared using the Mann-Whitney U-test. χ 2 analysis was used when comparing allele frequencies and categorical variables between the groups. The Hardy-Weinberg equilibrium was tested by a χ 2 test with 1 df. The adjusted odds ratios and 95% confidence interval (CI) for advanced GN at the time of renal biopsy with multivariate factors were calculated using logistic regression analysis. The Kaplan-Meier method and the Cox proportional hazards regression model were use to analyze the time course from the initial renal biopsy to the end point (initiation of dialysis or a doubling in the sCr level after the time of diagnosis). Covariates were selected by a stepwise backward method and the effects of these covariates were expressed by a hazard ratio. Values of p 0.05 were considered to indicate statistical significance. Statview 5.0 statistical software (Abacus Concepts, Inc., Berkeley, USA) was used for statistical analyses on a Macintosh G4 computer. 
Results
The 374 subjects consisting of 274 patients with histologically proven IgAN and 100 without any history of renal disease were genotyped for the SA polymorphism. Table 1 lists the distributions of genotypes and allele frequencies of the SA polymorphism in both groups. No difference in the SA genotype or the allele distribution was observed between them. The frequency of the minor allele, A2, was 0.153 and 0.155 in the IgAN and control groups, respectively. The expected frequency of the genotypes in each group, under the assumption of the Hardy-Weinberg equilibrium, did not differ from the observed genotype frequencies. Table 2 shows the clinical characteristics of subjects without any renal disease, and compares the clinical characteris- No difference between the two groups was observed for any of the clinical characteristics. Table 3 shows the clinical manifestations of the patients with IgAN and the comparisons between the two genotype groups. There were no differences in age, gender, body mass index (BMI), or urinary protein excretion between the two groups. The time from the first urinary abnormality to renal biopsy was also not statistically different. However, the CCr of patients with the A1A1 genotype was significantly lower than that observed with the other genotypes (A1A1 vs. A1A2/A2A2, 87.0 33.5 vs. 94.5 32.3, mean SD, respectively; p 0.05). Moreover, in contrast to the non-renal disease population, the systolic and diastolic blood pressure both at the time of renal biopsy and during observation tended to be higher in patients with the A1A1 genotype. The incidence of hypertension at the time of renal biopsy was also significantly higher in patients with the A1A1 genotype (A1A1 vs. A1A2/A2A2, 41.4 vs. 26.3%, respectively; p 0.05). To investigate whether the SA gene polymorphism affected the renal function at the time of renal biopsy independently of blood pressure, logistic regression analysis was conducted (Table 4 ). After adjusting for the effect of urinary protein excretion and hypertension, the SA genotype was no longer associated with advanced GN, suggesting that the effect of the gene polymorphism was indirect, occurring via the blood pressure.
Among all patients with IgAN (N 274), 86 (31.4%) progressed to ESRD during the mean follow-up duration of 93.4 67.3 months. The incidence of ESRD was numerically higher in patients with the A1A1 genotype of SA polymorphism, although the difference was not statistically significant. The effect of the SA gene polymorphism on renal survival was investigated by the Kaplan-Meier method ( Cox proportional hazards analysis was used to further test the significance of the genotype and other clinical covariates at the time of diagnosis as predictors of survival time (Table  5) . In this analysis, the SA genotype was no longer a significant risk factor for progression to ESRD after adjustment for other prognostic factors (hazard ratio, 0.977; 95% CI, 0.554 to 1.724; p 0.937). The independent predictive risk factors for the development of ESRD in the IgAN patients were a proteinuria level of more than 1 g/day, advanced GN, hypertension, and no administration of ACE-I.
Discussion
The results of the present study indicated that the SA gene polymorphism may have an association with high blood pressure and thus indirectly lead to a deterioration in the renal function of IgAN. Although the effect of the SA polymorphism on renal survival was not statistically significant, a higher proportion of IgAN patients with the A1 homozygote were hypertensive and their CCr was lower than those of patients with the other genotypes at the time of renal biopsy. Both of these clinical manifestations, hypertension and deteriorated renal function, were significant risk factors for the progression to ESRD. Osawa et al. have demonstrated that, even among IgAN patients with normal blood pressure, those with a blood pressure level of lower than 120 mmHg in systole and 80 mmHg in diastole show more mild renal histological damage and better renal function (15) . Thus the SA genotype was likely to have indirectly affected the renal prognosis through its effect on the blood pressure.
Interestingly, this association between the gene polymorphism and blood pressure was not observed within a population without renal disease. To date, we have no data or knowledge available to explain why the association between the SA gene polymorphism and blood pressure was observed only within patients with IgAN. However, the negative result observed in the control group may be inconclusive, because the number of subjects without renal disease in this study was relatively small. Nonetheless, these results may suggest that the impact of SA gene polymorphism on blood pressure is not the same between patients with and without renal involvement and that patients with renal injury have an increased sensitivity to this gene polymorphism.
The SA gene was originally isolated by virtue of its increased expression in the kidney of spontaneously hypertensive rats as compared with the kidney of normotensive WKY rats, and it has been proposed as a candidate gene for essential hypertension (11) . The SA gene is highly expressed in hypertensive kidneys, and its increased expression correlates with a rise of blood pressure in both SHR and Dahl rat models (8, 10) . Moreover, congenic substitution mapping studies have suggested that the SA gene is a candidate gene locus for hypertension (16) . Although the molecular mechanism in which the SA gene expression correlates with blood pressure remains to be elucidated, the subcellular distribution, and the structural and functional characteristics of the SA gene product have recently been demonstrated (17) . The SA protein is localized in the mitochondrial matrix, where it functions as an enzyme and plays a role in the oxidative degradation of medium-chain fatty acids for the production of energy. Considering the high energy consumption needed for active transport by Na ,K -ATPase in the proximal and distal renal tubules (18) , an alteration in the expression or the function of the SA gene may have an influence on the renal handling of electrolytes in tubular cells. It may also have an influence on the regeneration process of renal tubular cells after renal injury, and thus have an effect on the renal function of patients with glomerulonephritis. Further study is necessary to clarify the precise mechanism of the association between the SA polymorphism and either renal function or blood pressure. In particular, an investigation into whether the SA gene polymorphism is associated with the expression of the gene products in the renal tubular cells would help us to understand this issue. Recently, Iwai et al. demonstrated in a large population study that A/G polymorphism in intron 12 of the SA gene was associated with blood pressure. They also showed that this A/G polymorphism was associated with the expression level of SA mRNA in peripheral mononuclear cells in vivo (19) . The RFLP investigated in this study was located approximately 17 kb upstream from the A/G polymorphism investigated by Iwai et al. (19) . Although we have no data available as to whether or not the RFLP is in linkage disequilibrium with the A/G polymorphism in intron 12, further investigation of this matter might help clarify the mechanism of the association observed in this study.
We chose patients with IgAN as the subjects of this investigation because they were the largest homogeneous population for whom accurate clinical data were available both at the time of renal biopsy and during the clinical course. However, it is likely that the effect of the SA genetic polymorphism on the clinical manifestations observed in this study is not specific to IgAN, but that it affects the clinical phenotypes in other types of glomerular diseases. Investigations of patients with diabetic nephropathy, hypertensive nephropathy, and minimal change nephrotic syndrome are now in progress.
In conclusion, the present study demonstrates for the first time that the SA gene polymorphism may have an impact on the clinical manifestations of patients with renal injury, such as IgAN, which was not observed in the patients without renal involvement. Insight into these issues is not only of theoretical interest, but may lead to new approaches for specific therapies to replace the current use of antihypertensive or immunosuppressive drugs, which have substantial adverse effects. It is crucial to investigate the molecular mechanism by which the SA gene polymorphism specifically affects the blood pressure in patients with renal disease.
